PL2474545T3 - Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej - Google Patents
Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy JanusowejInfo
- Publication number
- PL2474545T3 PL2474545T3 PL11152714T PL11152714T PL2474545T3 PL 2474545 T3 PL2474545 T3 PL 2474545T3 PL 11152714 T PL11152714 T PL 11152714T PL 11152714 T PL11152714 T PL 11152714T PL 2474545 T3 PL2474545 T3 PL 2474545T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- pyridines
- pyrimidines
- kinase inhibitors
- heteroaryl substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74990505P | 2005-12-13 | 2005-12-13 | |
| US81023106P | 2006-06-02 | 2006-06-02 | |
| US85062506P | 2006-10-10 | 2006-10-10 | |
| US85687206P | 2006-11-03 | 2006-11-03 | |
| US85940406P | 2006-11-16 | 2006-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2474545T3 true PL2474545T3 (pl) | 2017-04-28 |
Family
ID=37903501
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11152708T PL2348023T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL11152723T PL2426129T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL11152714T PL2474545T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL06839328T PL1966202T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL11152730T PL2455382T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL16197502T PL3184526T3 (pl) | 2005-12-13 | 2006-12-12 | Pochodne pirrolo[2,3-D]pirymidyny jako inhibitory kinazy janusowej |
| PL11152677.8T PL2343299T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11152708T PL2348023T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL11152723T PL2426129T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06839328T PL1966202T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL11152730T PL2455382T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
| PL16197502T PL3184526T3 (pl) | 2005-12-13 | 2006-12-12 | Pochodne pirrolo[2,3-D]pirymidyny jako inhibitory kinazy janusowej |
| PL11152677.8T PL2343299T3 (pl) | 2005-12-13 | 2006-12-12 | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
Country Status (36)
| Country | Link |
|---|---|
| US (16) | US7598257B2 (pl) |
| EP (10) | EP3466953B1 (pl) |
| JP (4) | JP5017278B2 (pl) |
| KR (4) | KR101324737B1 (pl) |
| CN (4) | CN103214483B (pl) |
| AR (1) | AR057995A1 (pl) |
| AT (1) | ATE525374T1 (pl) |
| AU (1) | AU2006326548B2 (pl) |
| BR (1) | BRPI0619817B8 (pl) |
| CA (1) | CA2632466C (pl) |
| CR (2) | CR10065A (pl) |
| CY (8) | CY1112762T1 (pl) |
| DK (7) | DK2343299T3 (pl) |
| EA (3) | EA035795B1 (pl) |
| EC (2) | ECSP088540A (pl) |
| ES (9) | ES2700433T3 (pl) |
| FR (1) | FR17C1013I2 (pl) |
| HK (5) | HK1124840A1 (pl) |
| HR (7) | HRP20110903T1 (pl) |
| HU (7) | HUE028588T2 (pl) |
| IL (3) | IL192019A (pl) |
| LT (5) | LT3184526T (pl) |
| LU (1) | LU92137I2 (pl) |
| ME (1) | ME01312B (pl) |
| MX (1) | MX346183B (pl) |
| MY (2) | MY159449A (pl) |
| NZ (2) | NZ778831A (pl) |
| PL (7) | PL2348023T3 (pl) |
| PT (7) | PT2348023E (pl) |
| RS (7) | RS55576B1 (pl) |
| SG (3) | SG179430A1 (pl) |
| SI (7) | SI1966202T1 (pl) |
| TW (6) | TWI410407B (pl) |
| UA (2) | UA98449C2 (pl) |
| WO (1) | WO2007070514A1 (pl) |
| ZA (1) | ZA200805165B (pl) |
Families Citing this family (371)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2007031739A1 (en) * | 2005-09-16 | 2007-03-22 | Astrazeneca Ab | Heterobicyclic compounds as glucokinase activators |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| AU2006309013B2 (en) * | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| DK2343299T3 (en) | 2005-12-13 | 2016-01-18 | Incyte Holdings Corp | Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| SI1962830T1 (sl) * | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| CA2648250A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| EP2425858A3 (en) | 2006-11-20 | 2012-03-28 | President and Fellows of Harvard College | Compositions for treating pain and pruritus |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| ES2575797T3 (es) * | 2007-06-13 | 2016-07-01 | Incyte Holdings Corporation | Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2009003998A2 (en) * | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| AU2008317406B2 (en) * | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| EP2220068B1 (en) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| KR20130066703A (ko) * | 2008-02-06 | 2013-06-20 | 노파르티스 아게 | 피롤로［２,３ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도 |
| US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| PT2288610T (pt) | 2008-03-11 | 2016-10-17 | Incyte Holdings Corp | Derivados de azetidina e de ciclobutano como inibidores de jak |
| AU2009274454A1 (en) * | 2008-04-21 | 2010-01-28 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| WO2009132202A2 (en) * | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| EP2299816B1 (en) * | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2726844C (en) * | 2008-06-20 | 2016-08-30 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| SG178812A1 (en) * | 2008-06-20 | 2012-03-29 | Genentech Inc | Triazolopyridine jak inhibitor compounds and methods |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| DK2432472T3 (da) * | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
| EP2432555B1 (en) * | 2009-05-22 | 2014-04-30 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2764885C (en) | 2009-06-08 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011029043A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| BR112012005382A2 (pt) | 2009-09-10 | 2016-03-29 | Hoffmann La Roche | inibidores de jak |
| CN104892542B (zh) | 2009-10-02 | 2018-01-26 | 埃维克辛公司 | 抗炎症的2‑羰基噻唑和2‑羰基恶唑 |
| CA2777114C (en) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| US8389728B2 (en) * | 2009-11-06 | 2013-03-05 | The Arizona Board Of Regents | Pollen tube stimulants from Arabidopsis pistils |
| MX2012009541A (es) * | 2010-02-18 | 2012-10-01 | Incyte Corp | Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa. |
| WO2011109217A2 (en) * | 2010-03-02 | 2011-09-09 | Immunodiagnostics, Inc. | Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors |
| MX364636B (es) * | 2010-03-10 | 2019-05-03 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| WO2011130146A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| SG187742A1 (en) | 2010-08-20 | 2013-03-28 | Hutchison Medipharma Ltd | Pyrrolopyrimidine compounds and uses thereof |
| EP2619184B1 (en) * | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP2632903A4 (en) | 2010-10-28 | 2014-11-26 | Viamet Pharmaceuticals Inc | METALLOENZYMHEMMERVERBINDUNGEN |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| JP5917544B2 (ja) * | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| AU2011329734B2 (en) * | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| WO2012087881A1 (en) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| BR112013020798B1 (pt) * | 2011-02-18 | 2022-03-15 | Incyte Corporation | Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas |
| AU2012220601B2 (en) * | 2011-02-24 | 2017-03-09 | Cephalon, Inc. | Vinyl -aryl - sulfones for use in peritoneal carcinomatosis |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| MX2013013331A (es) * | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| MX344580B (es) | 2011-06-14 | 2016-12-20 | Novartis Ag | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| PE20181272A1 (es) | 2011-09-02 | 2018-08-03 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de pi3k |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2670878T3 (es) * | 2011-09-22 | 2018-06-01 | Merck Sharp & Dohme Corp. | Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa |
| CN103987713A (zh) * | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| BR112014013224B1 (pt) | 2011-11-30 | 2023-03-07 | Emory University | Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| DK3450434T3 (da) * | 2012-06-15 | 2021-05-03 | Concert Pharmaceuticals Inc | Deutererede derivater af ruxolitinib |
| SG11201408679XA (en) | 2012-06-26 | 2015-01-29 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| EP2877162A1 (en) | 2012-07-27 | 2015-06-03 | ratiopharm GmbH | Oral dosage forms for modified release comprising ruxolitinib |
| CN104507923B (zh) * | 2012-08-02 | 2018-02-09 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的取代的吡咯类活性剂 |
| US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
| MX2015002975A (es) * | 2012-10-26 | 2015-06-22 | Hoffmann La Roche | Inhibidores de la tirosina cinasa de bruton. |
| SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| EP3949953A1 (en) * | 2012-11-15 | 2022-02-09 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| WO2014085154A1 (en) | 2012-11-27 | 2014-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| SG11201503997VA (en) * | 2012-12-06 | 2015-06-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| KR102268357B1 (ko) | 2013-01-29 | 2021-06-23 | 아벡신 에이에스 | 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물 |
| WO2014126037A1 (ja) * | 2013-02-12 | 2014-08-21 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子及び照明装置 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| FI3786162T3 (fi) | 2013-05-17 | 2023-10-02 | Incyte Holdings Corp | Bipyratsolijohdannaisia jak-inhibiittoreina |
| PT3030227T (pt) | 2013-08-07 | 2020-06-25 | Incyte Corp | Formas de dosagem de libertação prolongada para um inibidor de jak1 |
| CA2921568A1 (en) | 2013-08-20 | 2015-02-25 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| WO2015054283A1 (en) * | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2015057695A1 (en) * | 2013-10-15 | 2015-04-23 | Bohan Jin | Novel compositions, uses and methods for their preparation |
| RU2016125133A (ru) | 2013-11-27 | 2018-01-09 | Новартис Аг | Комбинированная терапия, включающая применение ингибиторов jak, cdk и pim |
| EP3077395B1 (en) | 2013-12-05 | 2017-11-15 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CN104725380B (zh) * | 2013-12-18 | 2019-06-28 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| KR102261733B1 (ko) * | 2013-12-18 | 2021-06-04 | 콘서트 파마슈티컬즈, 인크. | 룩소리티닙의 중수소화된 유도체 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| SG11201607083VA (en) * | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| CN113583129A (zh) | 2014-03-14 | 2021-11-02 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
| EP3795152A1 (en) | 2014-04-08 | 2021-03-24 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| RU2564891C1 (ru) * | 2014-05-27 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул цитокининов |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016010886A1 (en) * | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
| CN112430250A (zh) | 2014-08-12 | 2021-03-02 | 莫纳什大学 | 定向淋巴的前药 |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN107001478B (zh) | 2014-10-14 | 2022-01-11 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| RS63963B1 (sr) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corp | Postupak pripreme pi3k inhibitora |
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| BR112017018908A2 (pt) | 2015-03-10 | 2018-04-17 | Aduro Biotech, Inc. | composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon |
| KR101859170B1 (ko) * | 2015-04-17 | 2018-05-17 | 광주과학기술원 | 트리아졸 화합물 및 이의 용도 |
| ES2734048T3 (es) * | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| AU2016301282B2 (en) | 2015-08-03 | 2022-03-17 | Children's Medical Center Corporation | Charged ion channel blockers and methods for use |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2017035366A1 (en) * | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| JP6802263B2 (ja) | 2015-09-02 | 2020-12-16 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2017041139A1 (en) | 2015-09-08 | 2017-03-16 | Monash University | Lymph directing prodrugs |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| PT3364958T (pt) | 2015-10-23 | 2023-04-10 | Navitor Pharm Inc | Moduladores de interação sestrina-gator2 e utilizações dos mesmos |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| US11370792B2 (en) | 2015-12-14 | 2022-06-28 | Raze Therapeutics, Inc. | Caffeine inhibitors of MTHFD2 and uses thereof |
| WO2017101777A1 (zh) * | 2015-12-15 | 2017-06-22 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物的盐 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| US20200261573A1 (en) | 2015-12-17 | 2020-08-20 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| JP6921087B2 (ja) * | 2015-12-31 | 2021-08-18 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | ルキソリチニブの合成プロセス |
| JP7011600B2 (ja) | 2016-01-12 | 2022-01-26 | ジェイムズ リチャード ベレンソン， | 被験体の免疫状態をモニタリングするための改善された方法 |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| WO2017129116A1 (zh) * | 2016-01-26 | 2017-08-03 | 杭州华东医药集团新药研究院有限公司 | 吡咯嘧啶五元氮杂环衍生物及其应用 |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| PL3426243T3 (pl) | 2016-03-09 | 2021-10-04 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
| ES2949357T3 (es) * | 2016-03-09 | 2023-09-28 | Raze Therapeutics Inc | Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| TWI828027B (zh) | 2016-03-28 | 2024-01-01 | 美商英塞特公司 | 作為tam抑制劑之吡咯并三嗪化合物 |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017192905A1 (en) | 2016-05-04 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| CN107513069A (zh) | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN107513067A (zh) * | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| WO2017223239A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| WO2018004306A1 (en) | 2016-06-30 | 2018-01-04 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JP6978097B2 (ja) * | 2016-07-26 | 2021-12-08 | スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. | Ｊａｋ阻害剤としての複素環化合物、該化合物の塩類および治療への使用 |
| KR20190035925A (ko) | 2016-08-24 | 2019-04-03 | 아르퀼 인코포레이티드 | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| IT201600092051A1 (it) * | 2016-09-13 | 2018-03-13 | Alessandro Antonelli | Composto medicale per il trattamento di tumori della tiroide |
| CN109952303B (zh) | 2016-10-14 | 2022-10-21 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| US10414727B2 (en) | 2016-11-08 | 2019-09-17 | Navitor Pharmaceuticals, Inc. | Phenyl amino piperidine mTORC inhibitors and uses thereof |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
| TWI783978B (zh) | 2017-03-08 | 2022-11-21 | 美商林伯士拉克許米公司 | Tyk2抑制劑、其用途及生產方法 |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| EP3615019A4 (en) | 2017-04-26 | 2021-01-27 | Navitor Pharmaceuticals, Inc. | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| AU2018273866B2 (en) | 2017-05-23 | 2021-09-30 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of Janus kinase inhibitors |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN107298680A (zh) * | 2017-07-12 | 2017-10-27 | 海门华祥医药科技有限公司 | 一种4‑氯‑7‑氮杂吲哚的生产工艺 |
| CA3070621A1 (en) | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3668887A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| EP4306524A2 (en) | 2017-08-29 | 2024-01-17 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| US11623932B2 (en) | 2017-09-22 | 2023-04-11 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| KR20200083553A (ko) | 2017-11-03 | 2020-07-08 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 |
| KR102034538B1 (ko) | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| EP3727362A4 (en) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| EP3731869A4 (en) | 2017-12-26 | 2021-09-22 | Kymera Therapeutics, Inc. | KINASES IRAQ DEGRADATION AGENTS AND THEIR USES |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3746071A4 (en) | 2018-01-29 | 2021-09-01 | Merck Patent GmbH | GCN2 INHIBITORS AND THEIR USES |
| MX2020007799A (es) | 2018-01-29 | 2020-09-18 | Merck Patent Gmbh | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. |
| AR114810A1 (es) | 2018-01-30 | 2020-10-21 | Incyte Corp | Procesos e intermedios para elaborar un inhibidor de jak |
| SG11202007805SA (en) | 2018-02-16 | 2020-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| AU2019229258B2 (en) | 2018-02-27 | 2023-09-14 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of TCR-Nck interaction |
| BR112020018135A2 (pt) | 2018-03-08 | 2020-12-22 | Novartis Ag | Uso de um anticorpo anti-p-selectina |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
| EP3775284A1 (en) | 2018-03-30 | 2021-02-17 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| US11059826B2 (en) | 2018-04-24 | 2021-07-13 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| PL3784666T3 (pl) | 2018-04-24 | 2022-07-18 | Merck Patent Gmbh | Związki przeciwproliferacyjne i ich zastosowania |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019233434A1 (zh) * | 2018-06-06 | 2019-12-12 | 杭州澳津生物医药技术有限公司 | 一种吡唑嘧啶衍生物及其用途和药物组合物 |
| KR20210021534A (ko) | 2018-06-15 | 2021-02-26 | 나비토르 파마슈티칼스 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020006408A1 (en) | 2018-06-29 | 2020-01-02 | Incyte Corporation | Formulations of an axl/mer inhibitor |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| US11021482B2 (en) | 2018-08-10 | 2021-06-01 | Adaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN113164419A (zh) | 2018-09-07 | 2021-07-23 | 皮克医疗公司 | Eif4e抑制剂和其用途 |
| WO2020081508A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN112955459A (zh) | 2018-10-23 | 2021-06-11 | 拜斯科技术开发有限公司 | 双环肽配体和其用途 |
| CA3117336A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 |
| CN113490484A (zh) | 2018-10-31 | 2021-10-08 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| MX2021006154A (es) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
| US11053241B2 (en) | 2018-11-30 | 2021-07-06 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| CN109394768B (zh) * | 2018-12-10 | 2019-08-23 | 牡丹江医学院 | 一种治疗湿疹的药物及其制备方法 |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CA3126034A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| CN111620873B (zh) * | 2019-02-28 | 2021-12-28 | 沈阳药科大学 | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AU2020234961A1 (en) | 2019-03-11 | 2021-09-30 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP2022527731A (ja) | 2019-03-11 | 2022-06-06 | ノシオン セラピューティクス，インコーポレイテッド | エステル置換イオンチャンネル遮断薬および使用方法 |
| MA55318A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques chargés et procédés d'utilisation |
| EP3941474A2 (en) | 2019-03-19 | 2022-01-26 | Incyte Corporation | Biomarkers for vitiligo |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| AU2020253990A1 (en) | 2019-04-02 | 2021-10-28 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| CA3134750A1 (en) | 2019-04-24 | 2020-10-29 | Jingdan Hu | A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor |
| US11420966B2 (en) | 2019-05-02 | 2022-08-23 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as JAK inhibitors |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| KR102286372B1 (ko) | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| AU2020290995A1 (en) | 2019-06-10 | 2022-04-07 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
| WO2020261219A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| US20220235043A1 (en) * | 2019-07-31 | 2022-07-28 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
| WO2021022076A1 (en) * | 2019-08-01 | 2021-02-04 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
| CA3150492A1 (en) | 2019-09-11 | 2021-03-18 | Donna L. Romero | USP30 INHIBITORS AND USES THEREOF |
| BR112022004451A2 (pt) | 2019-09-13 | 2022-06-21 | Nimbus Saturn Inc | Antagonistas de hpk1 e usos dos mesmos |
| KR20220063215A (ko) | 2019-09-16 | 2022-05-17 | 노파르티스 아게 | 골수섬유증의 치료를 위한 mdm2 억제제의 용도 |
| CN114423786A (zh) | 2019-09-16 | 2022-04-29 | 诺华股份有限公司 | 高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）IgG4抗体用于治疗骨髓纤维化的用途 |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US20210123931A1 (en) | 2019-10-10 | 2021-04-29 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| IL292612A (en) | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
| JP2023500890A (ja) | 2019-11-06 | 2023-01-11 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| IL292505A (en) | 2019-11-06 | 2022-06-01 | Nocion Therapeutics Inc | Charged ion channel blockers and methods of use |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| KR20220107213A (ko) | 2019-11-22 | 2022-08-02 | 인사이트 코포레이션 | Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법 |
| WO2021113665A1 (en) | 2019-12-05 | 2021-06-10 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics Inc | IRAQ DEGRADERS AND USES THEREOF |
| JP2023509394A (ja) | 2019-12-23 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｓｍａｒｃａ分解剤およびそれらの使用 |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111728975A (zh) * | 2020-02-25 | 2020-10-02 | 广东省检迅检测科技有限公司 | 用于减少运动损伤和促进运动损伤修复的组合物 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| MX2022011194A (es) | 2020-03-11 | 2022-11-08 | Nocion Therapeutics Inc | Bloqueadores de canales ionicos cargados y metodos de uso. |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| AR122505A1 (es) | 2020-06-02 | 2022-09-14 | Incyte Corp | Procesos para preparar un inhibidor de jak1 |
| AU2020451061A1 (en) | 2020-06-03 | 2022-12-15 | Incyte Corporation | Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| KR20230035031A (ko) | 2020-06-05 | 2023-03-10 | 킨네이트 바이오파마 인크. | 섬유아세포 성장 인자 수용체 키나아제의 억제제 |
| US20220023344A1 (en) | 2020-06-26 | 2022-01-27 | Crispr Therapeutics Ag | Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| US11751108B2 (en) * | 2020-08-05 | 2023-09-05 | Qualcomm Incorporated | Execution of reduced signaling handover |
| WO2022036030A1 (en) * | 2020-08-12 | 2022-02-17 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| EP4200300A1 (en) | 2020-08-18 | 2023-06-28 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| KR20230095923A (ko) | 2020-08-18 | 2023-06-29 | 인사이트 코포레이션 | Jak1 억제제를 제조하기 위한 공정 및 중간체 |
| WO2022061351A1 (en) | 2020-09-16 | 2022-03-24 | Incyte Corporation | Topical treatment of vitiligo |
| WO2022072814A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
| WO2022074600A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| WO2022074599A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| CN114437079A (zh) * | 2020-10-30 | 2022-05-06 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| KR102551758B1 (ko) | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
| CN117015531A (zh) | 2020-12-02 | 2023-11-07 | 医肯纳肿瘤学公司 | Tead抑制剂及其用途 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4255442A1 (en) | 2020-12-04 | 2023-10-11 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
| JP2023554665A (ja) | 2020-12-18 | 2023-12-28 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用 |
| US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
| WO2022165530A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| BR112023015584A2 (pt) | 2021-02-02 | 2023-10-24 | Liminal Biosciences Ltd | Antagonistas de gpr84 e usos dos mesmos |
| US20230113202A1 (en) | 2021-02-02 | 2023-04-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN116981669A (zh) * | 2021-02-05 | 2023-10-31 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| KR20230145446A (ko) | 2021-02-15 | 2023-10-17 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak4 분해제 및 이의 용도 |
| KR20230148208A (ko) | 2021-02-25 | 2023-10-24 | 임팩트 바이오메디신스, 인코포레이티드 | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 |
| JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| CA3215081A1 (en) | 2021-04-16 | 2022-10-20 | Alfredo C. Castro | Mek inhibitors and uses thereof |
| WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | EIF4E inhibitors and their uses |
| WO2023042224A1 (en) * | 2021-09-18 | 2023-03-23 | Natco Pharma Limited | An improved process for the preparation of ruxolitinib phosphate |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114044777B (zh) * | 2022-01-10 | 2022-04-19 | 南京佰麦生物技术有限公司 | 一种磷酸芦可替尼的制备方法 |
| CN114456181A (zh) * | 2022-02-21 | 2022-05-10 | 浙江乐普药业股份有限公司 | 一种芦可替尼的制备方法 |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
Family Cites Families (311)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| US4921947A (en) | 1986-03-31 | 1990-05-01 | Eli Lilly And Company | Process for preparing macrolide derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| KR0155955B1 (ko) * | 1989-10-11 | 1998-11-16 | 이따가끼 히로시 | 2 환성 피리미딘 유도체, 그의 제조방법 및 그를 유효성분으로 하는 의약제제 |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) * | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2167586T3 (es) | 1995-07-05 | 2002-05-16 | Du Pont | Pirimidinonas fungicidas. |
| IL122855A (en) | 1995-07-06 | 2004-08-31 | Novartis Ag | History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
| EP0952842A2 (en) | 1996-04-18 | 1999-11-03 | Merck & Co., Inc. | A method of treating cancer |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| CA2295620A1 (en) * | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| ID26698A (id) | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| AU5504599A (en) * | 1998-09-10 | 2000-04-03 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| AU3248600A (en) | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| ATE275141T1 (de) | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| EP1382339B1 (en) * | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| CZ301751B6 (cs) * | 1999-12-24 | 2010-06-09 | Aventis Pharma Limited | Bicyklický pyrrolový derivát, farmaceutická kompozice obsahující tento derivát, tato kompozice pro použití pri lécení a použití uvedeného derivátu pri výrobe léciva |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
| AU4878601A (en) | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| WO2001081346A2 (en) * | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| EP1294752A2 (en) | 2000-06-16 | 2003-03-26 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| AU2001274598A1 (en) | 2000-06-23 | 2002-01-02 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| NZ522364A (en) * | 2000-06-26 | 2004-09-24 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| AU1560802A (en) | 2000-06-28 | 2002-01-08 | Smithkline Beecham Plc | Wet milling process |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| EP1343781B1 (en) | 2000-12-05 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| US20040077654A1 (en) * | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| CA2446864C (en) * | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2455181C (en) | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| ATE420879T1 (de) | 2001-09-19 | 2009-01-15 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| PL211461B1 (pl) | 2001-10-30 | 2012-05-31 | Dana Farber Cancer Inst Inc | Zastosowanie pochodnych staurosporyny do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania białaczkom i zespołom mielodysplastycznym, preparat farmaceutyczny do leczenia białaczek i zestaw farmaceutyczny |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| AU2002224131A1 (en) * | 2001-11-30 | 2003-06-17 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| AU2003237807B2 (en) | 2002-04-15 | 2008-10-23 | Rb Health (Us) Llc | Sustained release of guaifenesin combination drugs |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| ATE381332T1 (de) | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
| WO2003094888A1 (en) * | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| WO2003099796A1 (en) | 2002-05-23 | 2003-12-04 | Cytopia Pty Ltd | Protein kinase inhibitors |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| CN1630668A (zh) * | 2002-06-26 | 2005-06-22 | 出光兴产株式会社 | 氢化共聚物及其制备方法以及包含氢化共聚物的热熔粘合剂组合物 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| AU2003278727A1 (en) | 2002-09-20 | 2004-04-08 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| DE60316013T2 (de) | 2002-11-04 | 2008-05-29 | Vertex Pharmaceuticals Inc., Cambridge | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| BR0316487A (pt) | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| PL1679074T3 (pl) * | 2003-10-24 | 2011-05-31 | Santen Pharmaceutical Co Ltd | Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| BRPI0416909A (pt) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
| AU2004305317A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection |
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| CN1918138B (zh) * | 2003-12-19 | 2011-05-04 | 先灵公司 | 作为cxc-和cc-趋化因子受体配体的噻二唑化合物 |
| KR101164258B1 (ko) | 2003-12-23 | 2012-07-11 | 아스텍스 테라퓨틱스 리미티드 | 단백질 키나아제 조절제로서의 피라졸 유도체 |
| US20050239806A1 (en) * | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| KR101216372B1 (ko) | 2004-03-30 | 2013-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| EP2363149A1 (en) | 2004-05-03 | 2011-09-07 | Novartis AG | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| CA2566158A1 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| MY144044A (en) | 2004-06-10 | 2011-07-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| EP1765819B1 (en) | 2004-06-30 | 2014-03-12 | Vertex Pharmaceuticals Inc. | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| JP2008515939A (ja) * | 2004-10-13 | 2008-05-15 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| DK1812440T3 (da) * | 2004-11-04 | 2011-01-31 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser |
| EP1885352A2 (en) | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| WO2006065916A1 (en) * | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| US20090124635A1 (en) | 2005-01-20 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
| ATE420883T1 (de) * | 2005-02-03 | 2009-01-15 | Vertex Pharma | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren |
| US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| JP2008533145A (ja) | 2005-03-15 | 2008-08-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| BRPI0610514A2 (pt) | 2005-04-05 | 2016-11-16 | Pharmacopeia Inc | composto, composição farmacêutica, e, método de tratamento de um distúrbio |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ZA200710379B (en) * | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| SI2395004T1 (sl) | 2005-06-22 | 2016-05-31 | Plexxikon Inc. | Derivati piro (2,3-b) piridina kot inhibitorji proteinske kinaze |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| EP2532667A1 (en) | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| WO2007044894A2 (en) | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| KR101315574B1 (ko) | 2005-10-14 | 2013-10-08 | 스미또모 가가꾸 가부시끼가이샤 | 히드라지드 화합물 및 이의 살충 용도 |
| WO2007049041A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| AU2006309013B2 (en) * | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| DK2343299T3 (en) * | 2005-12-13 | 2016-01-18 | Incyte Holdings Corp | Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| SI1962830T1 (sl) * | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| CN104650077A (zh) | 2006-01-17 | 2015-05-27 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| CA2635899A1 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| WO2007090141A2 (en) | 2006-02-01 | 2007-08-09 | Smithkline Beecham Corporation | Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| JP2009527554A (ja) | 2006-02-24 | 2009-07-30 | テバ ファーマシューティカル インダストリーズ リミティド | コハク酸メトプロロールｅ．ｒ．の錠剤およびその調製方法 |
| JPWO2007105637A1 (ja) * | 2006-03-10 | 2009-07-30 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| CA2648250A1 (en) | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| WO2007116313A2 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US20080051427A1 (en) | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| JP2009544625A (ja) * | 2006-07-20 | 2009-12-17 | メーメット・カーラマン | Ｒｈｏキナーゼのベンゾチオフェン阻害剤 |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| WO2008022164A2 (en) * | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
| RU2009112719A (ru) | 2006-09-08 | 2010-10-20 | Новартис АГ (CH) | Производные n-биарил(гетеро)арилсульфонамида, применимые в лечении заболеваний, опосредованных взаимодействием лимфоцитов |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| BRPI0718029A2 (pt) * | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| CN103288833B (zh) | 2006-11-22 | 2018-01-12 | 因塞特控股公司 | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| AU2007334436A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2118088B1 (en) * | 2006-12-20 | 2012-05-30 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| CN101534794A (zh) | 2006-12-22 | 2009-09-16 | 希格马托制药工业公司 | 用于递送眼科用药物的凝胶 |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR101514853B1 (ko) | 2007-03-01 | 2015-04-24 | 노파르티스 아게 | Ｐｉｍ 키나제 억제제 및 이들의 사용 방법 |
| CN101679423A (zh) | 2007-04-03 | 2010-03-24 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| ES2575797T3 (es) | 2007-06-13 | 2016-07-01 | Incyte Holdings Corporation | Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| NZ582188A (en) | 2007-07-11 | 2012-03-30 | Pfizer | Pharmaceutical compositions and methods of treating dry eye disorders |
| EP2183243A2 (en) * | 2007-08-01 | 2010-05-12 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | PROTEIN INHIBITORS PIM KINASES, COMPOSITIONS AND METHODS FOR TREATING CANCER |
| EP2220068B1 (en) | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| TR201815961T4 (tr) * | 2008-01-18 | 2018-11-21 | Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Yeni sitostatik 7-deazapürin nükleozidleri. |
| CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
| AR070531A1 (es) | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| PT2288610T (pt) * | 2008-03-11 | 2016-10-17 | Incyte Holdings Corp | Derivados de azetidina e de ciclobutano como inibidores de jak |
| WO2009115572A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| MX2010013562A (es) | 2008-06-26 | 2011-02-15 | Anterios Inc | Aplicacion dermica. |
| TWI461423B (zh) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之***吡啶化合物 |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| JP4884570B2 (ja) | 2008-08-20 | 2012-02-29 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| BRPI0918496A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
| CA2735782A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
| EA020136B1 (ru) | 2008-09-02 | 2014-08-29 | Новартис Аг | Производные пиколинамида в качестве ингибиторов киназы |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AU2009304508A1 (en) | 2008-10-17 | 2010-04-22 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| EP2432555B1 (en) | 2009-05-22 | 2014-04-30 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| CN102574857B (zh) | 2009-07-08 | 2015-06-10 | 利奥制药有限公司 | 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物 |
| WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SG10201405568UA (en) | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| CA2777114C (en) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| WO2011048082A1 (en) | 2009-10-20 | 2011-04-28 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| US8671402B2 (en) | 2009-11-09 | 2014-03-11 | Bank Of America Corporation | Network-enhanced control of software updates received via removable computer-readable medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| US9724410B2 (en) | 2009-11-24 | 2017-08-08 | Alderbio Holdings Llc | Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2011086053A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| BR112012019511A2 (pt) | 2010-02-05 | 2016-08-23 | Pfizer | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| MX2012009541A (es) * | 2010-02-18 | 2012-10-01 | Incyte Corp | Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa. |
| MX364636B (es) | 2010-03-10 | 2019-05-03 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| WO2011130146A1 (en) | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| WO2012003457A1 (en) | 2010-07-01 | 2012-01-05 | Mtm Research Llc | Anti-fibroblastic fluorochemical emulsion therapies |
| WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| AU2011329734B2 (en) | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| AU2011335882B2 (en) | 2010-12-03 | 2016-03-10 | Ym Biosciences Australia Pty Ltd | Treatment of JAK2-mediated conditions |
| BR112013020798B1 (pt) * | 2011-02-18 | 2022-03-15 | Incyte Corporation | Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| DK3450434T3 (da) | 2012-06-15 | 2021-05-03 | Concert Pharmaceuticals Inc | Deutererede derivater af ruxolitinib |
| EP2877162A1 (en) | 2012-07-27 | 2015-06-03 | ratiopharm GmbH | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| JP2015526520A (ja) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| EP3949953A1 (en) | 2012-11-15 | 2022-02-09 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| FI3786162T3 (fi) | 2013-05-17 | 2023-10-02 | Incyte Holdings Corp | Bipyratsolijohdannaisia jak-inhibiittoreina |
| PT3030227T (pt) | 2013-08-07 | 2020-06-25 | Incyte Corp | Formas de dosagem de libertação prolongada para um inibidor de jak1 |
| CA2921568A1 (en) | 2013-08-20 | 2015-02-25 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| SG11201607083VA (en) | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| EP3795152A1 (en) | 2014-04-08 | 2021-03-24 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| WO2020163653A1 (en) | 2019-02-06 | 2020-08-13 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2006
- 2006-12-12 DK DK11152677.8T patent/DK2343299T3/en active
- 2006-12-12 EP EP18191992.9A patent/EP3466953B1/en active Active
- 2006-12-12 KR KR1020127024523A patent/KR101324737B1/ko active IP Right Grant
- 2006-12-12 LT LTEP16197502.4T patent/LT3184526T/lt unknown
- 2006-12-12 ES ES16197502T patent/ES2700433T3/es active Active
- 2006-12-12 NZ NZ778831A patent/NZ778831A/en unknown
- 2006-12-12 CN CN201310058988.2A patent/CN103214483B/zh active Active
- 2006-12-12 EP EP20206996.9A patent/EP3838903B1/en active Active
- 2006-12-12 BR BRPI0619817A patent/BRPI0619817B8/pt active IP Right Grant
- 2006-12-12 TW TW095146502A patent/TWI410407B/zh active
- 2006-12-12 RS RS20170047A patent/RS55576B1/sr unknown
- 2006-12-12 JP JP2008545733A patent/JP5017278B2/ja active Active
- 2006-12-12 NZ NZ569015A patent/NZ569015A/en unknown
- 2006-12-12 HU HUE11152677A patent/HUE028588T2/hu unknown
- 2006-12-12 RS RS20160052A patent/RS54683B1/en unknown
- 2006-12-12 ES ES06839328T patent/ES2373688T3/es active Active
- 2006-12-12 DK DK11152714.9T patent/DK2474545T3/en active
- 2006-12-12 SG SG2012014957A patent/SG179430A1/en unknown
- 2006-12-12 EP EP16197502.4A patent/EP3184526B1/en active Active
- 2006-12-12 KR KR1020127024525A patent/KR101391900B1/ko active IP Right Grant
- 2006-12-12 PT PT111527081T patent/PT2348023E/pt unknown
- 2006-12-12 EP EP11152723.0A patent/EP2426129B1/en active Active
- 2006-12-12 HU HUE11152708A patent/HUE025173T2/hu unknown
- 2006-12-12 SG SG10201506912RA patent/SG10201506912RA/en unknown
- 2006-12-12 PT PT111527149T patent/PT2474545T/pt unknown
- 2006-12-12 RS RS20110571A patent/RS52101B/en unknown
- 2006-12-12 DK DK11152723.0T patent/DK2426129T3/en active
- 2006-12-12 SI SI200631209T patent/SI1966202T1/sl unknown
- 2006-12-12 AT AT06839328T patent/ATE525374T1/de active
- 2006-12-12 CA CA2632466A patent/CA2632466C/en active Active
- 2006-12-12 TW TW107113620A patent/TWI664182B/zh active
- 2006-12-12 PL PL11152708T patent/PL2348023T3/pl unknown
- 2006-12-12 RS RS20170081A patent/RS55634B1/sr unknown
- 2006-12-12 EP EP11152677.8A patent/EP2343299B9/en active Active
- 2006-12-12 US US11/637,545 patent/US7598257B2/en active Active
- 2006-12-12 SI SI200632020A patent/SI2343299T1/sl unknown
- 2006-12-12 SI SI200632133A patent/SI2455382T1/sl unknown
- 2006-12-12 PL PL11152723T patent/PL2426129T3/pl unknown
- 2006-12-12 RS RS20181405A patent/RS58113B1/sr unknown
- 2006-12-12 SG SG10202003901UA patent/SG10202003901UA/en unknown
- 2006-12-12 EP EP06839328A patent/EP1966202B1/en active Active
- 2006-12-12 CN CNA2006800527507A patent/CN101448826A/zh not_active Withdrawn
- 2006-12-12 PL PL11152714T patent/PL2474545T3/pl unknown
- 2006-12-12 ES ES11152677.8T patent/ES2561507T3/es active Active
- 2006-12-12 MY MYPI20082099A patent/MY159449A/en unknown
- 2006-12-12 ES ES11152714.9T patent/ES2612489T3/es active Active
- 2006-12-12 EP EP11152674.5A patent/EP2343298B9/en active Active
- 2006-12-12 EP EP11152708.1A patent/EP2348023B9/en active Active
- 2006-12-12 DK DK06839328.9T patent/DK1966202T3/da active
- 2006-12-12 CN CN201310059187.8A patent/CN103214484B/zh active Active
- 2006-12-12 DK DK11152730.5T patent/DK2455382T3/da active
- 2006-12-12 PT PT111527230T patent/PT2426129T/pt unknown
- 2006-12-12 DK DK16197502.4T patent/DK3184526T3/en active
- 2006-12-12 HU HUE11152730A patent/HUE030418T2/en unknown
- 2006-12-12 ES ES11152730.5T patent/ES2611588T3/es active Active
- 2006-12-12 ES ES18191992T patent/ES2867505T3/es active Active
- 2006-12-12 LT LTEP11152730.5T patent/LT2455382T/lt unknown
- 2006-12-12 EA EA201200132A patent/EA035795B1/ru active Protection Beyond IP Right Term
- 2006-12-12 UA UAA200809072A patent/UA98449C2/ru unknown
- 2006-12-12 TW TW101121442A patent/TWI468162B/zh active
- 2006-12-12 PT PT16197502T patent/PT3184526T/pt unknown
- 2006-12-12 ES ES11152708.1T patent/ES2543904T3/es active Active
- 2006-12-12 PT PT111527305T patent/PT2455382T/pt unknown
- 2006-12-12 PL PL06839328T patent/PL1966202T3/pl unknown
- 2006-12-12 SI SI200632137A patent/SI2474545T1/sl unknown
- 2006-12-12 AU AU2006326548A patent/AU2006326548B2/en active Active
- 2006-12-12 EA EA201691294A patent/EA036785B1/ru active Protection Beyond IP Right Term
- 2006-12-12 HU HUE11152714A patent/HUE032337T2/en unknown
- 2006-12-12 EP EP11152730.5A patent/EP2455382B1/en active Active
- 2006-12-12 TW TW103117669A patent/TW201434835A/zh unknown
- 2006-12-12 PT PT111526778T patent/PT2343299E/pt unknown
- 2006-12-12 PL PL11152730T patent/PL2455382T3/pl unknown
- 2006-12-12 RS RS20150513A patent/RS54181B9/sr unknown
- 2006-12-12 EA EA200870048A patent/EA019504B1/ru active Protection Beyond IP Right Term
- 2006-12-12 KR KR1020117029741A patent/KR101218214B1/ko active IP Right Grant
- 2006-12-12 TW TW103136068A patent/TWI553008B/zh active
- 2006-12-12 SI SI200632294T patent/SI3184526T1/sl unknown
- 2006-12-12 SI SI200632135A patent/SI2426129T1/sl unknown
- 2006-12-12 HU HUE11152723A patent/HUE030235T2/en unknown
- 2006-12-12 ES ES11152674.5T patent/ES2543903T3/es active Active
- 2006-12-12 ME MEP-2011-199A patent/ME01312B/me unknown
- 2006-12-12 CN CN201310058991.4A patent/CN103254190B/zh active Active
- 2006-12-12 HU HUE16197502A patent/HUE041382T2/hu unknown
- 2006-12-12 PL PL16197502T patent/PL3184526T3/pl unknown
- 2006-12-12 MY MYPI2013002970A patent/MY162590A/en unknown
- 2006-12-12 LT LTEP11152723.0T patent/LT2426129T/lt unknown
- 2006-12-12 ES ES11152723.0T patent/ES2612196T3/es active Active
- 2006-12-12 TW TW105120803A patent/TWI630207B/zh active
- 2006-12-12 PT PT06839328T patent/PT1966202E/pt unknown
- 2006-12-12 DK DK11152708.1T patent/DK2348023T5/da active
- 2006-12-12 UA UAA201115478A patent/UA116187C2/uk unknown
- 2006-12-12 SI SI200631956T patent/SI2348023T1/sl unknown
- 2006-12-12 RS RS20170079A patent/RS55632B1/sr unknown
- 2006-12-12 LT LTEP11152714.9T patent/LT2474545T/lt unknown
- 2006-12-12 PL PL11152677.8T patent/PL2343299T3/pl unknown
- 2006-12-12 MX MX2015003466A patent/MX346183B/es unknown
- 2006-12-12 WO PCT/US2006/047369 patent/WO2007070514A1/en active Application Filing
- 2006-12-12 EP EP11152714.9A patent/EP2474545B1/en active Active
- 2006-12-13 AR ARP060105499A patent/AR057995A1/es active IP Right Grant
-
2008
- 2008-06-05 IL IL192019A patent/IL192019A/en active IP Right Grant
- 2008-06-12 ZA ZA2008/05165A patent/ZA200805165B/en unknown
- 2008-06-12 CR CR10065A patent/CR10065A/es unknown
- 2008-06-12 US US12/138,082 patent/US8415362B2/en active Active
- 2008-06-13 EC EC2008008540A patent/ECSP088540A/es unknown
- 2008-07-11 KR KR1020087017011A patent/KR101216055B1/ko active IP Right Grant
-
2009
- 2009-03-06 HK HK09102199.6A patent/HK1124840A1/xx unknown
- 2009-03-06 HK HK12100384.0A patent/HK1160115A1/zh unknown
- 2009-08-27 US US12/549,170 patent/US8541425B2/en active Active
-
2011
- 2011-03-30 US US13/076,220 patent/US8530485B2/en active Active
- 2011-03-30 US US13/076,176 patent/US8946245B2/en active Active
- 2011-09-05 JP JP2011192962A patent/JP5710430B2/ja active Active
- 2011-12-01 HR HR20110903T patent/HRP20110903T1/hr unknown
- 2011-12-20 CY CY20111101270T patent/CY1112762T1/el unknown
-
2012
- 2012-01-12 HK HK12100362.6A patent/HK1160111A1/xx unknown
- 2012-01-26 HK HK12100761.3A patent/HK1160137A1/xx unknown
- 2012-03-08 EC ECSP12008540 patent/ECSP12008540A/es unknown
- 2012-11-22 HK HK12111990.3A patent/HK1171023A1/zh unknown
-
2013
- 2013-01-18 LU LU92137C patent/LU92137I2/fr unknown
- 2013-02-15 CY CY2013006C patent/CY2013006I2/el unknown
- 2013-09-06 US US14/020,505 patent/US9206187B2/en active Active
- 2013-09-20 US US14/033,039 patent/US8933086B2/en active Active
- 2013-10-03 CR CR20130506A patent/CR20130506A/es unknown
- 2013-12-17 JP JP2013260480A patent/JP5876026B2/ja active Active
-
2014
- 2014-04-08 IL IL231992A patent/IL231992A/en active IP Right Grant
- 2014-05-12 US US14/274,948 patent/US9079912B2/en active Active
-
2015
- 2015-05-13 US US14/711,576 patent/US20150238492A1/en not_active Abandoned
- 2015-07-06 JP JP2015135307A patent/JP6138865B2/ja active Active
- 2015-07-31 CY CY20151100673T patent/CY1116574T1/el unknown
- 2015-08-06 HR HRP20150837TT patent/HRP20150837T2/hr unknown
-
2016
- 2016-02-02 HR HRP20160112TT patent/HRP20160112T1/hr unknown
- 2016-06-03 US US15/173,057 patent/US9662335B2/en active Active
- 2016-08-10 US US15/233,652 patent/US9814722B2/en active Active
- 2016-11-13 IL IL248938A patent/IL248938A0/en unknown
- 2016-11-21 US US15/356,957 patent/US9974790B2/en active Active
-
2017
- 2017-01-19 HR HRP20170090TT patent/HRP20170090T1/hr unknown
- 2017-01-20 CY CY20171100089T patent/CY1118506T1/el unknown
- 2017-01-30 CY CY20171100130T patent/CY1118724T1/el unknown
- 2017-02-01 HR HRP20170162TT patent/HRP20170162T1/hr unknown
- 2017-02-07 HR HRP20170200TT patent/HRP20170200T1/hr unknown
- 2017-02-08 CY CY20171100171T patent/CY1118607T1/el unknown
- 2017-04-25 HU HUS1700017C patent/HUS1700017I1/hu unknown
- 2017-04-25 FR FR17C1013C patent/FR17C1013I2/fr active Active
- 2017-04-25 CY CY2017015C patent/CY2017015I1/el unknown
- 2017-04-25 LT LTPA2017012C patent/LTPA2017012I1/lt unknown
-
2018
- 2018-04-23 US US15/960,069 patent/US10398699B2/en active Active
- 2018-11-01 US US16/177,602 patent/US10639310B2/en active Active
- 2018-11-16 HR HRP20181912TT patent/HRP20181912T1/hr unknown
- 2018-12-27 CY CY20181101401T patent/CY1121202T1/el unknown
-
2020
- 2020-03-17 US US16/821,624 patent/US11331320B2/en active Active
-
2022
- 2022-03-08 US US17/689,510 patent/US11744832B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1700017I1 (hu) | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok | |
| HRP20180578T1 (hr) | Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze | |
| HK1168090A1 (zh) | 作為 激酶抑制劑的雜芳基取代的吡咯並 吡啶和吡咯並 嘧啶 |